News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
783,617 Results
Type
Article (65187)
Company Profile (685)
Press Release (717745)
Multimedia
Podcasts (100)
Webinars (12)
Section
Business (221145)
Career Advice (2930)
Deals (37778)
Drug Delivery (118)
Drug Development (86780)
Employer Resources (181)
FDA (17430)
Job Trends (16605)
News (374426)
Policy (36268)
Tag
Academia (2955)
Academic (1)
Accelerated approval (6)
Adcomms (24)
Allergies (93)
Alliances (53801)
ALS (97)
Alzheimer's disease (1478)
Antibody-drug conjugate (ADC) (146)
Approvals (17408)
Artificial intelligence (285)
Autoimmune disease (26)
Automation (16)
Bankruptcy (382)
Best Places to Work (12589)
BIOSECURE Act (22)
Biosimilars (115)
Biotechnology (472)
Bladder cancer (84)
Brain cancer (29)
Breast cancer (297)
Cancer (2401)
Cardiovascular disease (195)
Career advice (2450)
Career pathing (33)
CAR-T (168)
Cell therapy (466)
Cervical cancer (21)
Clinical research (70199)
Collaboration (904)
Company closure (1)
Compensation (568)
Complete response letters (25)
COVID-19 (2797)
CRISPR (46)
C-suite (262)
Cystic fibrosis (107)
Data (2284)
Decentralized trials (2)
Denatured (23)
Depression (53)
Diabetes (291)
Diagnostics (6848)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (130)
Drug pricing (118)
Drug shortages (31)
Duchenne muscular dystrophy (97)
Earnings (91940)
Editorial (45)
Employer branding (22)
Employer resources (154)
Events (124617)
Executive appointments (781)
FDA (18770)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (805)
Gene editing (115)
Generative AI (25)
Gene therapy (338)
GLP-1 (814)
Government (4921)
Grass and pollen (6)
Guidances (79)
Healthcare (20721)
Huntington's disease (25)
IgA nephropathy (29)
Immunology and inflammation (139)
Indications (30)
Infectious disease (2954)
Inflammatory bowel disease (152)
Inflation Reduction Act (10)
Influenza (56)
Intellectual property (101)
Interviews (508)
IPO (17375)
IRA (50)
Job creations (4504)
Job search strategy (2084)
Kidney cancer (11)
Labor market (39)
Layoffs (532)
Leadership (22)
Legal (8878)
Liver cancer (81)
Lung cancer (335)
Lymphoma (156)
Machine learning (7)
Management (63)
Manufacturing (335)
MASH (73)
Medical device (14486)
Medtech (14491)
Mergers & acquisitions (20963)
Metabolic disorders (760)
Multiple sclerosis (85)
NASH (22)
Neurodegenerative disease (106)
Neuropsychiatric disorders (32)
Neuroscience (2068)
NextGen: Class of 2025 (7506)
Non-profit (5057)
Now hiring (40)
Obesity (408)
Opinion (269)
Ovarian cancer (79)
Pain (100)
Pancreatic cancer (88)
Parkinson's disease (159)
Partnered (22)
Patents (251)
Patient recruitment (116)
Peanut (51)
People (62550)
Pharmaceutical (139)
Pharmacy benefit managers (21)
Phase I (21834)
Phase II (30644)
Phase III (23045)
Pipeline (1265)
Policy (167)
Postmarket research (3035)
Preclinical (9609)
Press Release (72)
Prostate cancer (113)
Psychedelics (35)
Radiopharmaceuticals (268)
Rare diseases (416)
Real estate (6923)
Recruiting (68)
Regulatory (24743)
Reports (47)
Research institute (2626)
Resumes & cover letters (468)
Rett syndrome (5)
RNA editing (5)
RSV (47)
Schizophrenia (79)
Series A (139)
Series B (91)
Service/supplier (28)
Sickle cell disease (56)
Special edition (18)
Spinal muscular atrophy (159)
Sponsored (30)
Startups (4024)
State (2)
Stomach cancer (14)
Supply chain (75)
Tariffs (46)
The Weekly (75)
Vaccines (765)
Venture capitalists (43)
Weight loss (281)
Women's health (35)
Worklife (18)
Date
Today (177)
Last 7 days (856)
Last 30 days (2828)
Last 365 days (35037)
2025 (11653)
2024 (37593)
2023 (42338)
2022 (53733)
2021 (58540)
2020 (57502)
2019 (50975)
2018 (38659)
2017 (35179)
2016 (35272)
2015 (41444)
2014 (36463)
2013 (33583)
2012 (33571)
2011 (34025)
2010 (32884)
Location
Africa (965)
Alabama (59)
Alaska (7)
Arizona (255)
Arkansas (14)
Asia (44438)
Australia (7779)
California (6478)
Canada (2072)
China (563)
Colorado (282)
Connecticut (304)
Delaware (161)
Europe (101548)
Florida (947)
Georgia (220)
Hawaii (1)
Idaho (62)
Illinois (605)
India (29)
Indiana (336)
Iowa (12)
Japan (171)
Kansas (111)
Kentucky (28)
Louisiana (14)
Maine (70)
Maryland (968)
Massachusetts (4965)
Michigan (245)
Minnesota (423)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (66)
New Hampshire (69)
New Jersey (1831)
New Mexico (30)
New York (1837)
North Carolina (1132)
North Dakota (9)
Northern California (2775)
Ohio (220)
Oklahoma (15)
Oregon (48)
Pennsylvania (1429)
Puerto Rico (13)
Rhode Island (36)
South America (1357)
South Carolina (24)
South Dakota (1)
Southern California (2410)
Tennessee (105)
Texas (970)
United States (24830)
Utah (194)
Virginia (170)
Washington D.C. (71)
Washington State (606)
West Virginia (3)
Wisconsin (70)
783,617 Results for "new chemical entities inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
December 11, 2024
·
6 min read
Pharm Country
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA) today announced that the Company’s lead product, YCANTH™, has received New Chemical Entity (“NCE”) Status and a listing in the Orange Book from the U.S. Food and Drug Administration (“FDA”), providing a minimum five years of regulatory exclusivity.
March 26, 2024
·
3 min read
BioMidwest
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Recursion announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration.
January 4, 2024
·
4 min read
Press Releases
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
October 4, 2024
·
5 min read
Press Releases
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
October 15, 2024
·
7 min read
Press Releases
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
July 22, 2024
·
7 min read
Press Releases
Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg
April 17, 2025
·
3 min read
Press Releases
PURE Bioscience Announces a New Distribution Agreement With Hydrite Chemical Company
January 21, 2025
·
6 min read
Deals
Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property
Medicure Inc. announces it has signed an asset purchase agreement with CanAm Bioresearch Inc. for the acquisition of the patent and intellectual property related to the discovery of new chemical entities that can be developed for therapeutic use.
June 24, 2024
·
9 min read
Press Releases
Kelyniam Global, Inc., (“KLYG”) Announces Private Investment to Public Entity (“PIPE”) Closure of Securities Offering
December 16, 2024
·
2 min read
1 of 78,362
Next
